无自发性早产史单胎妊娠短宫颈的宫颈环扎术:一项随机对照试验
这项多中心国际随机对照试验纳入无自发性早产史、中孕期经阴道超声宫颈长度≤25 mm的单胎妊娠孕妇,比较宫颈环扎术联合阴道黄体酮与单用阴道黄体酮。结果显示两组早产<35周发生率无显著差异(16.3% vs 23.4%;RR 0.70 [0.30-1.63]),但联合组从随机化到分娩的时间间隔及分娩孕周显著增加。
要点
- 无自发性早产史单胎妊娠宫颈长度≤25 mm者,环扎联合黄体酮较单用黄体酮未显著降低早产<35周发生率。
- 环扎联合黄体酮组从随机化到分娩的中位时间间隔较单用黄体酮组延长13天(5-20天),P=.01。
- 环扎联合黄体酮组分娩孕周较单用黄体酮组中位延后1.0周(0.2-1.7周),P=.035。
核心结论
- 在无自发性早产史、24周前经阴道超声宫颈长度≤25 mm的单胎妊娠中,环扎联合黄体酮较单用黄体酮未显著降低早产率,但显著延长了从随机化到分娩的时间间隔并使分娩孕周显著延后。
- 作者认为这些结果提示环扎联合黄体酮相对于单用黄体酮可能具有潜在获益。
- 该试验因入组缓慢提前终止,作者指出这些发现需在更大规模的试验或荟萃分析中证实。
研究设计与样本
- 多中心国际随机对照试验,2017年9月至2023年9月在美国和意大利的4个中心开展。
- 纳入标准:无自发性早产史的单胎妊娠,中孕期常规解剖超声检查时经阴道超声宫颈长度≤25 mm,孕周18 0/7至23 6/7周。
- 排除标准:当前或计划行宫颈环扎术、宫颈扩张、临产症状、感染、出血及筛查时胎膜破裂。
- 参与者按1:1随机分配至宫颈环扎术联合阴道黄体酮(每日阴道黄体酮200 mg)组或单用阴道黄体酮组,随机化按研究中心和宫颈长度≤15 mm分层。
- 计划样本量N=206,基于环扎术相对危险度估计0.54及标准治疗早产发生率34%;实际入组93例,3例排除(撤回1例、失访2例),意向性分析纳入90例(环扎联合黄体酮组43例,单用黄体酮组47例)。
主要发现
- 主要结局早产<35周在环扎联合黄体酮组为16.3%,单用黄体酮组为23.4%,相对危险度0.70(95%CI 0.30-1.63),无显著差异。
- 环扎联合黄体酮组从随机化到分娩的中位时间间隔较单用黄体酮组延长13天(95%CI 5-20天),P=.01。
- 环扎联合黄体酮组分娩孕周较单用黄体酮组中位延后1.0周(95%CI 0.2-1.7周),P=.035。
- Kaplan-Meier生存曲线显示环扎联合黄体酮组从随机化到分娩的时间间隔及分娩孕周均优于单用黄体酮组(Mantel-Cox log-rank检验P<.001和P=.003)。
- 上述发现在宫颈长度≤15 mm和16-25 mm两个亚组中均持续存在。
关键数值与推荐
- 主要结局早产<35周:环扎联合黄体酮组16.3% vs 单用黄体酮组23.4%(RR 0.70,95%CI 0.30-1.63)。
- 从随机化到分娩的中位时间间隔差异:环扎联合黄体酮组较单用黄体酮组延长13天(95%CI 5-20天),P=.01。
- 分娩孕周中位差异:环扎联合黄体酮组较单用黄体酮组延后1.0周(95%CI 0.2-1.7周),P=.035。
- 总体40例参与者(40.4%)经阴道超声宫颈长度≤15 mm。
临床怎么用
- 对于无自发性早产史、中孕期经阴道超声宫颈长度≤25 mm的单胎妊娠,环扎联合阴道黄体酮较单用阴道黄体酮未显著降低早产<35周发生率。
- 作者认为环扎联合黄体酮相对单用黄体酮可能具有潜在获益,但该试验提前终止,这些发现需在更大规模试验或荟萃分析中证实。
局限性
- 试验因入组缓慢提前终止。
- 作者指出这些发现需在更大规模的试验或荟萃分析中证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm birth remains a leading cause of neonatal morbidity and mortality. Cerclage for short cervical length ≤25 mm in patients with singleton pregnancies with a history of spontaneous preterm birth is associated with decreased neonatal morbidity/mortality. Both vaginal progesterone and cerclage individually have level 1 evidence supporting benefit in the prevention of preterm birth in pregnancies complicated by short cervical length. However, there is a paucity of level 1 evidence regarding the potential benefit of cerclage with progesterone relative to progesterone alone for short cervical length ≤25 mm in patients with singleton pregnancies without a history of spontaneous preterm birth. OBJECTIVE: This study aimed to conduct a pragmatic randomized controlled trial to evaluate the additional benefit of cerclage with vaginal progesterone relative to vaginal progesterone alone in patients with singleton pregnancies without prior spontaneous preterm birth and with a current midtrimester transvaginal ultrasound cervical length ≤25 mm. STUDY DESIGN: This was a multicenter international randomized controlled trial conducted from September 2017 to September 2023, involving 4 sites in the United States and Italy. Patients with singleton pregnancies without prior spontaneous preterm birth received transvaginal ultrasound cervical length (universal) screening during the midtrimester anatomy ultrasound examination as part of routine care. Inclusion criteria included transvaginal ultrasound cervical length ≤25 mm at 18 0/7 to 23 6/7 weeks. Exclusion criteria included current or planned cerclage, cervical dilation, symptoms of labor, infection, bleeding, and rupture of membranes at screening. Participants were randomized in a 1:1 ratio to cerclage with vaginal progesterone (200-mg vaginal progesterone daily) or vaginal progesterone alone. Randomization was stratified by study site and transvaginal ultrasound cervical length ≤15 mm. The primary outcome was preterm birth <35 weeks, assessed using intention-to-treat analysis. Secondary outcomes included preterm birth <37, 32, 28, and 24 weeks, gestational age at delivery, latency to delivery, and neonatal outcomes. Categorical variables were compared using the Pearson chi-square test and relative risk estimates with 95% confidence intervals. Continuous variables were compared using the Mann-Whitney U test. Latency to delivery and gestational age at delivery were also compared using Kaplan-Meier survival curves. Planned enrollment was set at N=206 on the basis of an estimated 0.54 relative risk with cerclage and a 34% incidence of preterm birth with standard care. The trial was registered on ClinicalTrials.gov (NCT03251729) on June 22, 2017. RESULTS: Enrollment ran from September 22, 2017 to October 31, 2023, and was halted early because of lagging enrollment. A total of 93 participants were randomized; 3 were excluded because of withdrawal (n=1) and loss to follow-up (n=2). Of the 90 participants included in the intention-to-treat analysis, 43 were assigned to cerclage and progesterone and 47 to progesterone alone. Overall, 40 participants (40.4%) had a transvaginal ultrasound cervical length ≤15 mm. There was no significant difference in the primary outcome of preterm birth <35 weeks between those randomized to cerclage with progesterone vs progesterone alone (16.3% vs 23.4%; relative risk, 0.70 [0.30-1.63]). Those randomized to cerclage with progesterone had significantly increased latency from randomization to delivery (median difference, 13 [5-20] days; P=.01) and a significantly later gestational age at delivery (median difference, 1.0 [0.2-1.7] weeks; P=.035). A Kaplan-Meier survival curve also demonstrated increased latency to delivery and gestational age at delivery for cerclage with progesterone compared with progesterone alone (Mantel-Cox log-rank P<.001 and P=.003, respectively). These findings persisted within both subgroups of cervical length ≤15 mm and 16 to 25 mm. CONCLUSION: In singleton gestations without a prior spontaneous preterm birth and a transvaginal ultrasound cervical length ≤25 mm before 24 weeks, cerclage with progesterone was not found to significantly reduce the preterm birth rate compared with progesterone alone. However, cerclage and progesterone did result in a significantly longer latency from randomization to delivery and a significantly later gestational age at delivery, compared to progesterone alone. These results suggest the potential benefit of cerclage and progesterone relative to progesterone alone in patients with singleton pregnancies without a prior spontaneous preterm birth and a short cervical length ≤25 mm before 24 weeks. This trial was halted early, and these findings should be confirmed in a larger trial or meta-analysis. El resumen está disponible en Español al final del artículo.
引用
- Boelig RC, Tersigni C, Di Simone N, et al. Cerclage in singleton pregnancies with no prior spontaneous preterm birth and short cervix: a randomized controlled trial. Am J Obstet Gynecol MFM. 2025. PMID: 39880123. doi:10.1016/j.ajogmf.2025.101602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。